Skip to content

Sleep disruption in quadriplegia, its hormonal basis and a randomized controlled trial (RCT) of melatonin supplementation

Study examining whether daily administration of 3mg melatonin alters subjective sleep experience and sleep architecture in people with complete quadriplegia

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12609000714280
Enrollment
30
Registered
2009-08-19
Start date
2009-08-25
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

People with complete quadriplegia commonly report sleep disturbances and have been found to lack melatonin production, a hormone that modulates our sleep cycle. It is unclear if their sleep problems are related to their lack of melatonin production. The aim of this study was to investigate whether nightly supplementation of 3mg melatonin would induce, shift the phase of and/or modify subjective sleep for people with complete quadriplegia. It is hypothesised that supplementation with melatonin will improve subjective sleep for people with complete quadriplegia along with their sleep phasing, quality of life and autonomic functioning.

Interventions

3 week within subject trial of daily evening administration of 3mg melatonin delivered orally. Randomised, double-blind, placebo controlled trial with two-week washout period between intervention and placebo treatments

Sponsors

Austin Health
Lead SponsorHospital

Study design

Allocation
Randomised controlled trial
Primary purpose
Treatment

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

Complete (motor and sensory) quadriplegia (T1 or higher lesion), time since spinal cord injury is greater than one year (chronic)

Exclusion criteria

Travel across three or more time zones within three weeks or during protocol, Pregnancy or breast feeding, Ongoing use of over-the-counter melatonin

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026